News & AnalysisInfectious Disease

Approval of Novel TB Drug Celebrated—With Restraint

See allHide authors and affiliations

Science  11 Jan 2013:
Vol. 339, Issue 6116, pp. 130
DOI: 10.1126/science.339.6116.130

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The U.S. Food and Drug Administration approved the drug, bedaquiline, for only patients who have multidrug-resistant tuberculosis, which can require up to 2 years of treatment. It is the first new tuberculosis drug to be green-lighted in more than 40 years, but the celebration was tempered as sobering challenges face the drug's wide scale use.